Melanoma Clinical Trials

The melanoma clinical trials being conducted at Moffitt Cancer Center provide patients with novel opportunities to try exciting new treatments and be among the first to benefit from them. Through these important research studies, physicians are able to evaluate innovative treatment options and compare them with the current best practices. As a result, the standard of care, which is the best treatment currently available based on past research, improves continually for the benefit of all patients.

A patient’s eligibility for participating in melanoma clinical trials is carefully determined by considering several factors for each particular study. To ensure accuracy and help researchers achieve meaningful results, potential participants are screened based on characteristics like age, gender, type and stage of cancer, past treatments and overall health and wellness.

Once a patient qualifies for a clinical trial, he or she must then decide whether to participate. At Moffitt, we work carefully with our patients to make sure they have all the information they need to make informed choices. With regard to clinical trials for melanoma, our team will explain:

  • What the study will entail and how it might affect the patient’s daily life
  • How the proposed treatment compares with the standard of care
  • The risks and benefits associated with the treatment under study
  • Potential side effects
  • The requirements of participation, including testing, hospitalization and physician visits
  • Other available treatment options
  • Whether long-term follow-up care will be needed

Moffitt is the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, and we continue to lead the way in cancer research. Our multispecialty team of melanoma experts works collaboratively to ensure that each patient receives highly individualized, supportive care, whether that includes a clinical trial or other advanced treatment option.

If you would like to learn about the melanoma clinical trials currently underway at Moffitt Cancer Center, you do not need a referral to consult with our cancer experts. Please call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online.

Helpful Links:

 

calledFromCancerPage=True - substr=
testProtocol=

Open Clinical Trials:

Showing of 50

CLINICAL TRIAL 18989

A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 19327

A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients with Metastatic Melanoma or Non-small Cell Lung Cancer with Untreated Brain Metastases

Disease Site: Non small cell lung cancer, Brain and Nervous System, Lung, Melanoma, skin, Gliomas

View Trial Details

CLINICAL TRIAL 19441

Pilot Study of Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 20162

Phase 1 Trial of Intralesional Immunotherapy with IFx-Hu2.0 Vaccine in Patients with Advanced Merkel Cell Carcinoma or Cutaneous Squamous Cell Carcinoma

Disease Site: Melanoma, skin, Merkel cell carcinoma (neuroendocrine skin cancer), Other Skin, Skin, Squamous Cell Carcinoma (SCC)

View Trial Details

CLINICAL TRIAL 20270

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors (IOV-COM-202)

Disease Site: Lung, Melanoma, skin, Non small cell lung cancer

View Trial Details

CLINICAL TRIAL 20313

Neoadjuvant Immunotherapy with Intratumoral Tavokinogene Telseplasmid (Tavo) plus Electroporation in Combination with Intravenous Nivolumab in Patients with Operable Locally- Regionally Advanced Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 20494

A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 20641

A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 20854

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Disease Site: Melanoma, skin, Other Skin

View Trial Details

CLINICAL TRIAL 20904

A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in Braf-V600 Mutant Melanoma with Brain Metastases

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 20956

A Two-Part, Phase 1a/B, Open-Label, Multicenter Trial Evaluating Pharmacokinetics, Safety and Efficacy Of PF-07284890 (ARRY-461) In Participants With BRAF V600-Mutant Solid Tumors With And Without Brain Involvement

Disease Site: Any Site, Brain and Nervous System, Larynx, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Skin, Brain metastasis, Gliomas

View Trial Details

CLINICAL TRIAL 21112

Phase 2 Study of Axitinib + Ipilimumab in Advanced Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 21179

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects with Advanced Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 21180

A First-in-Human, Two-Part, Open-Label, Clinical Study to Assess the Safety, Tolerability and Activity of Intravenous Doses of ICT01 as Monotherapy and in Combination with an Immune Checkpoint Inhibitor, in Patients with Advanced-Stage, Relapsed/Refractory Cancer (EVICTION Study)

Disease Site: Any Site, Breast, Colon, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Ovary, Prostate, Stomach, Urinary Bladder

View Trial Details

CLINICAL TRIAL 21239

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 21344

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Melanoma (Morpheus-Melanoma)

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 21573

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients with Hepatic Dominant Ocular Melanoma

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 90015

Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Disease Site: Breast, Lung, Melanoma, skin, Ovary, Pancreas, Urinary Bladder

View Trial Details

CLINICAL TRIAL 21125

MElanoma Research Lymph Node Prediction Implementation National_001 (MERLIN_001)

Disease Site: Melanoma, skin

View Trial Details

CLINICAL TRIAL 50401

Creation of Cell Lines and Corresponding DNA and RNA Analysis from Acral Lentiginous Malignant Melanoma

Disease Site: Melanoma, skin

View Trial Details